← FDA DRUG APPROVALS

FDA NDA · NDA212641

LIBERVANT

Sponsor: AQUESTIVE

APPLICATION
NDA212641
TYPE
NDA
ROUTE
BUCCAL
DOSAGE FORM
FILM
MARKETING STATUS
None (Tentative Approval)

Products

LIBERVANTNone (Tentative Approval)
DIAZEPAM 20MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 15MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 10MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 5MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 17.5MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 12.5MG · FILM · BUCCAL
LIBERVANTNone (Tentative Approval)
DIAZEPAM 7.5MG · FILM · BUCCAL

Approval history

2022-08-30Type 9 - New Indication Submitted as Distinct NDA, Consolidated with Original NDA after Approval · Original · standardLetterTA
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →